The first P-III study evaluates ecnoglutide (qw, SC) in ~210 treatment-naïve patients at ~35 sites in China & the second P-III trial evaluates XW003 vs dulaglutide in ~600 patients at ~60 sites in China for 52wks. followed by a 5wk. follow-up period
In the P-I & II studies, Ecnoglutide showed treatment benefits for patients with T2D and obesity & was found to be safe and well tolerated. The therapy also showed robust HbA1c & weight reductions in the P-II trial
Ecnoglutide is a novel, long-acting glucagon-like peptide-1 analog that has been designed for improved biological activity, cost-effective manufacturing, and qw dosing. The company plans to initiate the pivotal study of ecnoglutide for obesity shortly
Ref: PR Newsswire | Image: Sciwind
Related News:- Sciwind Biosciences Reports P-IIb Trial Interim Results of XW003 (ecnoglutide) for the Treatment of Obesity
